CGTN: UK Regulator Criticized for 'Act of Censorship' by Banning CGTN
10.3.2021 16:24:00 EET | Business Wire | Press release
Britain's communications regulator Ofcom has been criticized for its decision to ban and fine China Global Television Network (CGTN) for political reasons.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005537/en/
CGTN headquarters building in Beijing. /CFP
A group of journalists, filmmakers and artists recently challenged Ofcom's "act of censorship" in an open letter published by the No Cold War campaign and the Morning Star.
"The decision by Ofcom to remove the broadcasting license of CGTN is an act of censorship which is not in the interests of Britain and its people," the open letter said, calling the move an "attack on free speech."
Ofcom revoked the license of CGTN to broadcast in the UK in early February on the grounds of its ultimate control and its political attributes. Beijing slammed the move as political repression against Chinese media.
In their letter, the signatories questioned Ofcom's justification for banning CGTN.
"Ofcom's justification for taking CGTN off air is that any holder of a broadcasting license in Britain must not be controlled by political bodies. However, this law is only selectively applied. Numerous private and state channels have clear political agendas or control – the BBC itself, for example, which had its staff vetted by MI5, has not had its broadcasting license revoked," it said.
The letter urged Ofcom to reverse its decision and reinstate CGTN's license.
CGTN committed to balanced reporting
A spokesperson for CGTN on Tuesday called on the British regulator to calmly listen to the opinions expressed in the letter and end its political crackdown on Chinese media.
The spokesperson said that as an international news channel, CGTN is committed to providing "accurate, timely and objective news and information with diverse and balanced views" for its global audiences.
"China is increasingly connected and engaged with the rest of the world including the UK," the spokesperson said in a statement. "It is our responsibility to present Chinese viewpoints and perspectives in our news reporting, which is what our viewers expect and is also in the interest of the public."
'The world should be able to hear China's voice'
In a separate statement on Tuesday, CGTN said it is disappointed with and firmly opposes Ofcom's latest sanction decisions and adjudications against it.
Ofcom on Monday fined CGTN 225,000 British pounds (about $310,933) for "breaching rules on fairness, privacy and due impartiality" just weeks after it stripped the network of its right to air in Britain.
"CGTN believes its coverage of the 2019 violent protests in the Hong Kong Special Administrative Region was fair, truthful and duly impartial," the statement said.
"As a news outlet from China, CGTN made it possible for global audiences to see and hear a more complete picture of events in Hong Kong by reporting on the voices opposing violence and destruction," it stressed. "The fact that CGTN has been sanctioned by Ofcom for its objective coverage of the event is unjust."
"It is in the public interest that the world should be able to hear China's voice and perspective and see the true picture more clearly," it added.
At a regular press briefing on Tuesday, Chinese Foreign Ministry spokesperson Zhao Lijian urged Ofcom and certain individuals to immediately cease engaging in political manipulation and correct their mistakes, slamming the move as "blatant political oppression."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005537/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
